重组人血管内皮抑制素/恩度,Recombinant human endostatin/Endostar
1)Recombinant human endostatin/Endostar重组人血管内皮抑制素/恩度
2)Rh-endostatin/Endostar重组人血管内皮抑制素/恩度
3)Rh-endostatin/Endostar重组人血管内皮抑素/恩度
4)new rh-endostatin or endostar新型重组人血管内皮抑素/恩度
5)recombinant human Endostatin重组人血管内皮抑制素
1.Clinical application of recombinant human endostatin重组人血管内皮抑制素临床应用进展
2.The fermentation process of recombinant human Endostatin expression in Escherichia coli BL21 (DE3) was studied.优化了重组人血管内皮抑制素的E。
3.In order to instruct reasonable application of the recombinant Human Endostatin ,the development in clinical research of Endostar for malignant tumor were reviewed in this paper,including clinical results,drug adverse reactions and qulity of life.介绍重组人血管内皮抑制素(恩度)治疗恶性肿瘤的临床研究情况,包括临床疗效、不良反应和生活质量方面的研究进展,为临床合理应用和评价新药提供参考。
英文短句/例句

1.Clinical application of recombinant human endostatin重组人血管内皮抑制素临床应用进展
2.Biological Properties and Recombinant Human Vascular Endostatin Therapy of Hemangioma: Study on Hemangioma Endothelial Cells in Vitro Culture血管瘤内皮细胞的生物特性和重组人血管内皮抑制素对血管瘤内皮细胞作用的实验研究
3.Clinical observation of the efficacy of intrapleural injection of endostar in treatment of malignant pleural effusion重组人血管内皮抑制素胸膜腔内注射治疗癌性胸水的临床观察
4.Human Recombinated Endostatin Combined with Chemical Drugs for the Treatment of Breast Cancer in Animal Study;重组人血管内皮抑制素联合化疗药物治疗乳腺癌的动物实验研究
5.Development in clinical research of Endostar for malignant tumor重组人血管内皮抑制素(恩度)治疗恶性肿瘤的临床研究进展
6.Clinical efficiency of rh-endostatin combined with vincristine and cisplatin in the treatment of non-small cell lung cancer重组人血管内皮抑制素联合NP方案治疗晚期非小细胞肺癌的疗效
7.Specific and Quantitative Detection of Recombinant Human Endostatin by Double Antibody Sandwich ELISA重组人血管内皮抑制素的双抗体夹心ELISA特异性定量检测
8.ENDOSTAR COMBINED IFL REGIMEN IN TREATMENT OF ADVANCED COLORECTAL CANCER:AN OBSERVATION OF 30 CASES重组人血管内皮抑制素联合IFL方案治疗晚期结肠癌30例临床分析
9.Clinical observation of endostar in the treatment of malignant serous cavity effusion重组人血管内皮抑制素治疗恶性胸腹腔积液的临床观察
10.Effects of recombinant human endostatin (endostar) combined of cisplatin on the growth of lung cancer in nude mouse重组人血管内皮抑制素联合顺铂治疗肺癌的实验研究
11.Rh-endostatin injection combined with chemotherapy on the advanced malignancies重组人血管内皮抑制素联合化疗治疗晚期恶性肿瘤的临床观察
12.Clinical study of rh-endostatin combined with chemotherapy for advanced gastric cancer重组人血管内皮抑制素联合化疗治疗晚期胃癌的临床观察
13.Recombinant human endostatin combined with chemotherapy in treatment of advanced malignant tumors重组人血管内皮抑制素联合化疗治疗多种晚期恶性肿瘤
14.Effect of endostar on proliferation and cell cycle of lung cancer microvasculature endothelial cell HPMEC重组人血管内皮抑制素对肺微血管内皮细胞增殖及其周期分布的影响
15.Effects of endostar on human lymph endothelial cell cytoskeleton and tube-like formation重组人血管内皮抑制素对淋巴管内皮细胞骨架及淋巴管生成的影响
16.Endostar combined with chemotherapy as first line therapy for the treatment of stage Ⅳ melanoma,a phase Ⅱ clinical study重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究
17.Experimental Study on the Inhibition of Corneal Neovascularization with Recombinant Human Endostatin;重组人内皮抑素抑制角膜新生血管的实验研究
18.The Experimental Study of Recombinant Human Endostatin Inhibiting on Corneal Neovascularization of Rats;重组人内皮抑素对大鼠角膜新生血管抑制作用的实验研究
相关短句/例句

Rh-endostatin/Endostar重组人血管内皮抑制素/恩度
3)Rh-endostatin/Endostar重组人血管内皮抑素/恩度
4)new rh-endostatin or endostar新型重组人血管内皮抑素/恩度
5)recombinant human Endostatin重组人血管内皮抑制素
1.Clinical application of recombinant human endostatin重组人血管内皮抑制素临床应用进展
2.The fermentation process of recombinant human Endostatin expression in Escherichia coli BL21 (DE3) was studied.优化了重组人血管内皮抑制素的E。
3.In order to instruct reasonable application of the recombinant Human Endostatin ,the development in clinical research of Endostar for malignant tumor were reviewed in this paper,including clinical results,drug adverse reactions and qulity of life.介绍重组人血管内皮抑制素(恩度)治疗恶性肿瘤的临床研究情况,包括临床疗效、不良反应和生活质量方面的研究进展,为临床合理应用和评价新药提供参考。
6)Homemade human rh-endostatin重组人血管内皮抑制素
1.Observation of early curative effect of homemade human rh-endostatin injection in combination with chemotherapy for advanced non-small cell lung cancer;重组人血管内皮抑制素联合化疗治疗晚期非小细胞肺癌近期疗效观察
延伸阅读

舒血管素 ,血管舒缓素药物名称:血管舒缓素英文名:Kallidinogenase别名: 保妥丁;激太积放酶;舒血管素 ,血管舒缓素外文名:Kallidinogenase适应症: 用于脑动脉硬化症、闭塞性动脉内膜炎、闭塞性血管炎、四肢慢性溃疡、肢端动脉痉挛症、手足发绀、老年性四肢冷感、中央视网膜炎、眼底出血等。也用于冠心病、心绞痛、视网膜血流障碍。 用量用法: 1.注射:临用时溶解(每1.5ml10单位)后进行肌注或皮注1次量10~20单位,每日1~2次。轻症每日10单位,以3周为1疗程。眼科亦可作眼结膜下注射,每次5单位。 2.口服:每次1片(含10单位),空腹时服。 注意事项: 1.凡肿瘤、颅内压增高、心力衰竭病人忌用。 2.有些病人应用后可出现疼痛反应。 3.本品对热、酸、碱、氧化剂均不稳定。 规格: 注射用血管舒缓素:每支10单位。片剂:每片10单位。 类别:周围血管扩张药